Biocompatible Peritoneal Dialysis Fluids: Clinical Outcomes
Peritoneal dialysis (PD) is a preferred home dialysis modality and has a number of added advantages including improved initial patient survival and cost effectiveness over haemodialysis. Despite these benefits, uptake of PD remains relatively low, especially in developed countries. Wider implementat...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | International Journal of Nephrology |
| Online Access: | http://dx.doi.org/10.1155/2012/812609 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832557093862768640 |
|---|---|
| author | Yeoungjee Cho Sunil V. Badve Carmel M. Hawley Kathryn Wiggins David W. Johnson |
| author_facet | Yeoungjee Cho Sunil V. Badve Carmel M. Hawley Kathryn Wiggins David W. Johnson |
| author_sort | Yeoungjee Cho |
| collection | DOAJ |
| description | Peritoneal dialysis (PD) is a preferred home dialysis modality and has a number of added advantages including improved initial patient survival and cost effectiveness over haemodialysis. Despite these benefits, uptake of PD remains relatively low, especially in developed countries. Wider implementation of PD is compromised by higher technique failure from infections (e.g., PD peritonitis) and ultrafiltration failure. These are inevitable consequences of peritoneal injury, which is thought to result primarily from continuous exposure to PD fluids that are characterised by their “unphysiologic” composition. In order to overcome these barriers, a number of more biocompatible PD fluids, with neutral pH, low glucose degradation product content, and bicarbonate buffer have been manufactured over the past two decades. Several preclinical studies have demonstrated their benefit in terms of improvement in host cell defence, peritoneal membrane integrity, and cytokine profile. This paper aims to review randomised controlled trials assessing the use of biocompatible PD fluids and their effect on clinical outcomes. |
| format | Article |
| id | doaj-art-4cdf5b05d31c40e889e429992a9a404f |
| institution | Kabale University |
| issn | 2090-214X 2090-2158 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Nephrology |
| spelling | doaj-art-4cdf5b05d31c40e889e429992a9a404f2025-02-03T05:43:37ZengWileyInternational Journal of Nephrology2090-214X2090-21582012-01-01201210.1155/2012/812609812609Biocompatible Peritoneal Dialysis Fluids: Clinical OutcomesYeoungjee Cho0Sunil V. Badve1Carmel M. Hawley2Kathryn Wiggins3David W. Johnson4Department of Nephrology, Princess Alexandra Hospital, University of Queensland, Level 2, ARTS Building, 199 Ipswich Road, Woolloongabba, Brisbane QLD 4102, AustraliaDepartment of Nephrology, Princess Alexandra Hospital, University of Queensland, Level 2, ARTS Building, 199 Ipswich Road, Woolloongabba, Brisbane QLD 4102, AustraliaDepartment of Nephrology, Princess Alexandra Hospital, University of Queensland, Level 2, ARTS Building, 199 Ipswich Road, Woolloongabba, Brisbane QLD 4102, AustraliaDepartment of Nephrology, Royal Melbourne Hospital, Melbourne, VIC 3050, AustraliaDepartment of Nephrology, Princess Alexandra Hospital, University of Queensland, Level 2, ARTS Building, 199 Ipswich Road, Woolloongabba, Brisbane QLD 4102, AustraliaPeritoneal dialysis (PD) is a preferred home dialysis modality and has a number of added advantages including improved initial patient survival and cost effectiveness over haemodialysis. Despite these benefits, uptake of PD remains relatively low, especially in developed countries. Wider implementation of PD is compromised by higher technique failure from infections (e.g., PD peritonitis) and ultrafiltration failure. These are inevitable consequences of peritoneal injury, which is thought to result primarily from continuous exposure to PD fluids that are characterised by their “unphysiologic” composition. In order to overcome these barriers, a number of more biocompatible PD fluids, with neutral pH, low glucose degradation product content, and bicarbonate buffer have been manufactured over the past two decades. Several preclinical studies have demonstrated their benefit in terms of improvement in host cell defence, peritoneal membrane integrity, and cytokine profile. This paper aims to review randomised controlled trials assessing the use of biocompatible PD fluids and their effect on clinical outcomes.http://dx.doi.org/10.1155/2012/812609 |
| spellingShingle | Yeoungjee Cho Sunil V. Badve Carmel M. Hawley Kathryn Wiggins David W. Johnson Biocompatible Peritoneal Dialysis Fluids: Clinical Outcomes International Journal of Nephrology |
| title | Biocompatible Peritoneal Dialysis Fluids: Clinical Outcomes |
| title_full | Biocompatible Peritoneal Dialysis Fluids: Clinical Outcomes |
| title_fullStr | Biocompatible Peritoneal Dialysis Fluids: Clinical Outcomes |
| title_full_unstemmed | Biocompatible Peritoneal Dialysis Fluids: Clinical Outcomes |
| title_short | Biocompatible Peritoneal Dialysis Fluids: Clinical Outcomes |
| title_sort | biocompatible peritoneal dialysis fluids clinical outcomes |
| url | http://dx.doi.org/10.1155/2012/812609 |
| work_keys_str_mv | AT yeoungjeecho biocompatibleperitonealdialysisfluidsclinicaloutcomes AT sunilvbadve biocompatibleperitonealdialysisfluidsclinicaloutcomes AT carmelmhawley biocompatibleperitonealdialysisfluidsclinicaloutcomes AT kathrynwiggins biocompatibleperitonealdialysisfluidsclinicaloutcomes AT davidwjohnson biocompatibleperitonealdialysisfluidsclinicaloutcomes |